iTeos Therapeutics has raised $75 million (€64 million) to take two immuno-oncology assets into the clinic. The MPM Capital-led series B tees iTeos up to start dosing patients with an adenosine A2A antagonist later this year while expanding into new offices in Cambridge, Massachusetts. Belgium-based iTeos first made waves in 2014 when Pfizer paid €24 million for the rights to its IDO1 inhibitor. That program took a hit at the turn of the year when lackluster efficacy in a phase 1 brain cancer trial prompted Pfizer to walk away, and was subsequently blown away as an Incyte-triggered storm engulfed the once-hyped IDO space. But iTeos has recovered quickly from the setback.